Orthofix International N.V.

NASDAQ:OFIX

Brad Mason - President & CEO

March 2017
 Safe Harbor Statement and Use of Non-GAAP Measures

Except for historical information contained herein, the statements made in this presentation
constitute forward looking statements that involve certain risks and uncertainties. These forward
looking statements are based on our beliefs and expectations as of February 27, 2017, and we
do not undertake any obligation to revise or update such forward looking statements. Certain
factors may cause actual results to differ materially from those contained in the forward looking
statements, including those risks detailed from time to time in the Companys reports on file at
the Securities and Exchange Commission.

Orthofix may use certain non-GAAP financial measures in its presentations. Orthofix may use
non-GAAP financial measures as supplemental measures of performance and believes these
measures can provide useful information to investors in evaluating our operations, period over
period. However, non-GAAP financial measures have limitations as analytical tools, and should
not be considered in isolation or as a substitute for Orthofixs financial results prepared in
accordance with GAAP. In addition, investors should note that any non-GAAP financial measures
Orthofix uses may not be the same non-GAAP financial measures, and may not be calculated in
the same manner, as that of other companies. Investors can find reconciliations of our non-GAAP
financial measures to the most directly comparable GAAP financial measures in our earnings
press releases.

2
 Orthofix is a bone fusion company focused
on the design, manufacture and distribution
of a broad range of regenerative and repair
products worldwide.

3
 By The Numbers

2016NetSalesof$410million
TTMAdjustedEBITDAof$79.3million
TTMROIC*of10.6%
Globalpresenceinover70countries
Salesbreakdown:US 77%OUS 23%
CashonDecember30,2016of$40million
Nodebt
$125millioncreditfacilityavailable
Recentlycompleteda$75millionstockrepurchase
*Using38%taxrate

4
 Constant Currency Net Sales and Adjusted EBITDA

NetSales AdjustedEBITDA

2.5%CAGR

$400
$100 14.1%CAGR
$350 $90
$300 $80
$70
$250
$60
$200
$50
$150 $40

$100 $30
$20
$50
$10
$0 $0
2014 2015 2016 2017 2014 2015 2016 2017
Guidance Guidance
CCNetSales* GuidanceRange CCAdj.EBITDA* GuidanceRange

*March09,2017foreignexchangeratesusedforcalculations

5
 Bone Regeneration and Repair

BIOSTIM REGENERATION BIOLOGICS

EXTREMITY FIXATION
REPAIR SPINE FIXATION

6
 Our Strategic Business Units

SBU 2016 NET SALES

Strategic Business Unit 2016 Net Sales ($M)

BioStim $176
18%

Biologics $58
43%

25% Extremity Fixation $103

14% Spine Fixation $73

Total Net Sales $410

7
 BioStim Bone Growth Stimulation

* MarketSize:$500MMarketShare:35%MarketPosition:#1
AnnualMarketGrowthRate:1% 3%

Pulsed Electromagnetic Field technology (PEMF)

Strong clinical data and PMA Class III approval
Market leading spine and cervical products
CervicalStim device is only FDA-approved product for cervical spine
CAGR of 6% since 2013
Products primarily sold in the U.S.

8 *InternalEstimates
 FDA and CE Mark Approval for Next-Gen CervicalStim
and SpinalStim Devices

Bluetooth connectivity and mobile app (Stim

OnTrack) designed to facilitate patient
compliance and improve spinal fusion outcomes
Enables physicians to receive real-time data on
patients adherence to their prescribed
treatment protocol
Many new patient comfort and convenience
features

9
 BioStim Policy Recommendation from NASS

North American Spine Societys (NASS)

Coverage Policy Recommendations
Released October 2016
First-of-its-kind coverage recommendations
for electrical bone growth stimulators
Specifically supports the use of PEMF
devices
Clinical evidence-based recommendations
Both cervical and lumbar regions

10
 Biologics Stem Cell Allograft

* MarketSize:$275MMarketShare:21%MarketPosition:#2
AnnualMarketGrowthRate:3% 5%

Human cellular and tissue-based business

Long-term partnership with Musculoskeletal Transplant Foundation (MTF)
Partners since 2008; current agreement runs to 2025
Trinity ELITE allograft tissue has surgeon preference advantages
Products primarily sold in the U.S.

11 *InternalEstimates
 Extremity Fixation

* MarketSize:$800MMarketShare:13%MarketPosition:#5
(ExternalFixation) AnnualMarketGrowthRate:2% 4%

Leader in external fixation fracture repair, deformity correction and bone

reconstruction
Primarily external fixation devices, with complimentary internal fixation products
Ring fixation, pin-to-bar, plates, screws, nails
~35% of revenue from pediatric procedures
~75% of revenue from outside of the U.S.

12 *InternalEstimates
 Spine Fixation

* MarketSize:$9.0BMarketShare:1%MarketPosition:#9
AnnualMarketGrowthRate:1% 3%

Implants for spine surgeries

Orthofix has a full line of outstanding spinal implants
Cervical & Lumbar
Degenerative Disc Disease
MIS
Deformity Correction
Continuous stream of new products 12 in 2016
~80% of revenue from the U.S.

13 *InternalEstimates
 Well Positioned For The Future

14
 Achievement Highlights Since 2013
People
NewManagementTeam
ReconstitutedBoardofDirectors
CultureofIntegrity&Performance
PerformanceBasedCompensation
Products
Investmentin:
BasicScience&ClinicalResearch
ObtainingTuckInTechnologies
ProlificnewproductPipeline
OrthofixofToday
15
Processes
FinancialControls
WorldwideOracle&ITUpgrades
SimplifiedCorporate&SBUStructures
OrdertoCashProcessImprovements
Performance
Adj.EBITDAExpansion~500BPS
FreeCashFlowOutlook
TTMDoubleDigitROIC
ResolvedLegacySEC/DOJIssues
 Looking Ahead

OrthofixofToday
LowSingleDigitTopLineGrowthCompany
~20%AdjustedEBITDAMargins
StrongFreeCashFlowPotential
DoubleDigitROIC
OpportunitytoLeverage:
LeadershipTeam
Infrastructure
FinancialStrength

TheNextChapter
Creatingadditionalshareholdervalue

16
 2017 Organic Strategy

Leverage our expanded distribution networks and

new product pipeline to accelerate sales growth in
each of our SBUs

Increase utilization of our BioStim products

Clinical research to increase the number of
applications, find new indications and support
reimbursement
Leverage NASS coverage recommendations to
expand patient access to this treatment

Continue to increase Adjusted EBITDA, free cash

flow and ROIC

17
 2017 Inorganic Strategy

Evaluate our current portfolio and structure to

maximize shareholder value
Acquire tuck-in products, technologies and distribution
that will drive sales in our existing businesses
Opportunistically pursue more substantial value
accretive acquisitions that leverage our market leading
positions
To us value accretive means:
Strong strategic fit to strengthen our business
ROIC at least equal to WACC within planning period
Accretive to EPS in relative near term
Risk commensurate with strategic and financial
opportunity

18
 Summary of Investment Highlights

Diversified business focused on bone fusion

Market leading position in bone growth stimulation
Global distribution footprint
Multiple avenues of growth opportunity
Investing in core technologies
Accelerating Free Cash Flow
Double-digit TTM ROIC
Strong balance sheet

19
Thank You
NASDAQ: OFIX
www.orthofix.com

Investor Relations Mark Quick

markquick@orthofix.com

ORTHOFIXINC2017
February27,2017